NCT03442972View on ClinicalTrials.gov

Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

December 1, 2021

Conditions
Hyperlipidemias
Interventions
DRUG

Teduglutide

Teduglutide

DRUG

Placebo

Placebo

Trial Locations (2)

M5G 2C4

Toronto General Hopital, Toronto

M5T 3A9

Kensington Screening Clinic, Toronto

All Listed Sponsors
collaborator

Kensington Screening Clinic

UNKNOWN

lead

University Health Network, Toronto

OTHER

NCT03442972 - Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids | Biotech Hunter | Biotech Hunter